Clinical Trials List
2022-01-10 - 2028-12-01
Phase III
Recruiting6
ICD-10C50.011
Malignant neoplasm of nipple and areola, right female breast
ICD-10C50.012
Malignant neoplasm of nipple and areola, left female breast
ICD-10C50.019
Malignant neoplasm of nipple and areola, unspecified female breast
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9174.0
Malignant neoplasm of female breast, nipple and areola
-
Trial Applicant
ELI LILLY AND COMPANY(TAIWAN), INC.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
- 林燕淑 無
- Jiun-I Lai 無
- Yi-Fang Tsai 無
- Chun-Yu Liu 無
- Chi-Cheng Huang 無
- 馮晉榮 無
- 賴亦貞 無
- 邱仁輝 無
- Ta-Chung Chao 無
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Yung-Chang Lin 無
- Chan-Keng Yang 無
- 沈士哲 無
- Mengting Peng 無
- Shin-Cheh Chen Division of General Surgery
- Wen-Chi Shen 無
- 周旭桓 無
- Wen-Ling Kuo 無
- 阮昱翔 無
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 甘蓉瑜 無
- Junping Shiau Shiau 無
- Chieh-Han Chuang 無
- 巫承哲 無
- Shen Liang Shih 無
- Chung-Liang Li 無
- Fang-Ming Chen 無
- 高理鈞 無
- 高捷妮 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
20-36 participants
-
Global
350 participants
